Please login to the form below

Not currently logged in
Email:
Password:

Alexion Pharmaceuticals adds to its board

Judith Reinsdorf recently worked at Johnson Controls

Alexion Pharmaceuticals has appointed Judith Reinsdorf to its board of directors following her role as executive vice president and general counsel of Johnson Controls.

Reinsdorf, who has a background in corporate governance and expertise in managing corporate and legal affairs, has served in various positions for companies including Tyco International and Monsanto.

David Brennan, chairman of the board, said: “We are pleased to welcome Judy to Alexion’s board of directors.

“She brings strong corporate governance and legal expertise, with a proven track records in global compliance, strategic planning, data privacy and regulatory matters.

“Her broad experience at large US public companies, both within and outside the healthcare industry, will be a valuable addition to our board.”

Reinsdorf joins at a time when the company aims to “strengthen its leadership position in rare diseases”.

She said: “I am excited to join Alexion’s board of directors at a pivotal time for the company as it executes its strategy to deliver sustainable growth and I look forward to applying my experience to help guide Alexion’s future success.”

In addition, director Ann Veneman has also announced that she does not plan to stand for re-election as she will be retiring following eight years of service.

5th March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics